Quick Answer
Denali Therapeutics Inc. reported Earnings Per Share Diluted of $2.97 (loss) per share for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -15.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Denali Therapeutics Inc.'s Earnings Per Share Diluted has declined by 661.5%.
- Historical annual values: Fiscal year 2025: $2.97 (loss) per share | Fiscal year 2024: $2.57 (loss) per share | Fiscal year 2023: $1.06 (loss) per share | Fiscal year 2022: $2.60 (loss) per share | Fiscal year 2021: $2.39 (loss) per share | Fiscal year 2020: $0.63 per share | Fiscal year 2019: $2.07 (loss) per share | Fiscal year 2018: $0.39 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: